Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.16
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.16
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume85.07K
Average Volume (3M)208.17K
Market Cap
C$16.93M
Enterprise ValueC$18.29
Total Cash (Recent Filing)C$245.06K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding109,236,030
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and positive equity (~$1.93M) materially reduce solvency and interest-rate risk for an early-stage biotech. This lowers fixed financing costs, improves flexibility to fund GMP compliance and trial-related inventory, and supports execution while pursuing scalable revenue.
Improving Revenue TractionSustained double-digit revenue growth (+42.5% TTM) signals improving commercial traction supplying regulated MDMA for trials. For a niche GMP supplier, continued top-line scaling can spread fixed costs, move gross margins toward parity, and underpin a path to cash-flow stability if demand persists.
Specialized Regulated Supplier ModelOperating as a regulated GMP supplier to clinical sponsors creates structural barriers to entry (compliance, quality controls, controlled-substance licensing). These attributes can foster sticky, high-margin relationships and predictable demand from trials and research over the medium term.
Bears Say
Persistent Negative Cash FlowNearly $1M of negative operating and free cash flow on a $1.27M revenue base indicates ongoing burn that will necessitate external financing or dilution unless revenues scale or costs are cut. Persistent cash outflows constrain investment in capacity, compliance, and commercialization.
Unprofitable Core OperationsNegative gross profit and sizable operating losses show the current cost structure exceeds product economics. Without sustained margin improvement from scale, pricing, or cost reductions, profitability remains distant, raising long-term viability and dilution risk for stakeholders.
Limited Visible Long-term PartnershipsAbsence of disclosed long-term commercial partners or recurring royalties limits revenue visibility and predictability. Reliance on one-off trial orders increases volatility in demand and complicates forecasting, making it harder to plan capex or secure favorable, non-dilutive financing.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$16.93M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Dec 18, 2026 which is in 136 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Jul 29, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 109,236,030 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.